Tesamorelin
A synthetic analog of growth-hormone-releasing hormone (GHRH) studied for endocrine signalling, lipid metabolism, and pulsatile growth-hormone axis research.
⏱ Half-Life
Short–Moderate duration profile
Tesamorelin demonstrates a short–moderate half-life characteristic in research literature, shaping how observation windows and study timelines are typically structured.
⚡ Onset Characteristics
Gradual measurable response
Onset is observed as gradual — a property that influences how researchers structure comparative studies versus other compounds in the signalling research category.
🧠 Key Notes
What makes it distinct
- 01Stabilised GHRH structure for extended research window
- 02Frequently compared with CJC-1295 in endocrine studies
- 03Investigated for visceral lipid metabolism pathways
🧬 Mechanism of Action
How it works
Tesamorelin is a stabilised 44-amino-acid analog of human growth-hormone-releasing hormone (GHRH), with a trans-3-hexenoic acid modification that protects against enzymatic degradation. It binds the GHRH receptor on pituitary somatotroph cells, stimulating endogenous growth hormone secretion in a natural pulsatile pattern. Unlike exogenous GH administration, it preserves physiological feedback loops and downstream IGF-1 signalling. Its effect on visceral adipose tissue is particularly well-characterised — IGF-1 and GH together promote lipolysis preferentially in visceral fat depots while sparing subcutaneous fat.
✨ Documented Benefits
What the research shows it supports
🔍 Research Insights
What the literature shows
FDA-approved for HIV-associated lipodystrophy — one of the few peptides in the library with full clinical-trial pharmacology data.
Preferentially reduces visceral adipose tissue while preserving subcutaneous fat in published studies.
Preserves natural pulsatile GH release, making it a more physiologic comparator than continuous GH administration.
🧪 Typical Research Use Cases
Where it appears in study design
Visceral adiposity and lipid metabolism research.
GH-axis modulation in endocrine models.
Comparative work vs CJC-1295 + Ipamorelin blends.
🔬 Study Deep Dive
Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation
Stanley TL, et al. · JAMA · 2014
6-month randomised, double-blind, placebo-controlled trial.
50 HIV-positive adults with abdominal fat accumulation and hepatic steatosis.
Tesamorelin 2 mg subcutaneously daily vs placebo.
Significant reduction in visceral adipose tissue (−18%) and hepatic fat fraction versus placebo, with preserved glucose control.
Confirmed that GHRH-analogue restoration of endogenous pulsatile GH selectively reduces visceral and hepatic fat — the primary evidence base for tesamorelin.
📚 References
Peer-reviewed literature
Primary research sources cited on this profile. All links resolve to PubMed or the publishing journal.
- [01]
Falutz, J. et al. (2007). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304.
J Clin Endocrinol Metab ↗ - [02]
Stanley, T. L. et al. (2014). Effects of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 312(4), 380–389.
JAMA ↗ - [03]
Falutz, J. et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370.
New England Journal of Medicine ↗ - [04]
Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy, 46(2), 240–247.
Annals of Pharmacotherapy ↗
⚠️ Not Medical Advice
Educational research summary only
This profile summarises published research on Tesamorelin. It is not medical advice, diagnosis, or treatment, and it is not intended to promote human use, self-administration, or the substitution of professional healthcare. Discuss any health decision with a licensed clinician.
Continue Exploring
Also explore: CJC-1295 + Ipamorelin, MOTS-c, Retatrutide